FDA Inspection 1179906 — Central Pennsylvania Blood Bank Headquarters
The FDA completed an inspection of Central Pennsylvania Blood Bank Headquarters on Sep 1, 2022 in Hummelstown, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 1, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Hummelstown, PA (United States)